BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/340/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 01:53:41 2024-06-14 pm EDT | ||
| 13.41 EUR | +2.52% |
|
| Current month | +29.44% | ||
| 1 month | +67.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 13.41 | +2.52% |
| 24-06-13 | 13.08 | +1.95% |
| 24-06-12 | 12.83 | -3.46% |
| 24-06-11 | 13.29 | -0.82% |
| 24-06-10 | 13.4 | -0.81% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:53 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM5PE0 |
| ISIN | DE000VM5PE08 |
| Date issued | 2023-11-17 |
| Strike | 340 $ |
| Maturity | 2024-06-21 (7 Days) |
| Parity | 10 : 1 |
| Emission price | 3.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.63 € |
|---|---|
| Lowest since issue | 3.71 € |
| Spread | 0.22 € |
| Spread % | 1.65% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
